Huateng Pharma Introduces Y-Shape PEG NHS
Changsha, China, 2024-Jul-24 — /EPR Network/ — Huateng Pharma, a global leader in PEG derivatives and a premier CDMO for APIs and intermediates, is excited [read full press release…]
Articles by timmy7433
Huateng Pharmace to Showcase Innovations at CPHI China 2024
Shanghai, China, 2024-Jul-10 — /EPR Network/ — Hunan Huateng Pharmaceutical Co., Ltd., a global leader in the production of PEG derivatives and Contract Development and Manufacturing [read full press release…]
Huateng Pharma Launches New Innovative Product: Piroctone Olamine
Hunan, China, 2024-Jul-01 — /EPR Network/ — Huateng Pharma, a leading Contract Development and Manufacturing Organization (CDMO), is proud to announce the launch of its [read full press release…]
Discover Cutting-Edge Solutions at CPhI Japan 2024 with Huateng Pharma
Hunan, China, 2024-Mar-31 — /EPR Network/ — Hunan Huateng Pharmaceutical Co., Ltd, a global leader in PEG derivatives and Contract Development and Manufacturing Organization (CDMO) [read full press release…]
Huateng Pharma Proudly Unveils Its New Product – Semaglutide Side Chains
Changsha, China, 2024-Mar-10 — /EPR Network/ — Huateng Pharma, a distinguished provider of premium pharmaceutical intermediates, proudly unveils its latest breakthrough: Semaglutide Side Chain. This [read full press release…]
Huateng Pharma’s Featured Product Line: Veterinary API and Intermediates
Hunan, China, 2024-Jan-21 — /EPR Network/ — Huateng Pharma, a Contract Development and Manufacturing Organization (CDMO) specializing in APIs and intermediates, is proud to announce [read full press release…]
Huateng Pharma Unveils Premium Ingredients for Commodities and Cosmetics
Hunan, China, 2023-Dec-30 — /EPR Network/ — Huateng Pharma, a leading supplier of high-quality ingredients for the pharmaceutical and cosmetic industries, is proud to announce [read full press release…]
Huateng Pharma Introduces Anti-Diabetes Intermediates
Hunan, China, 2023-Nov-19 — /EPR Network/ — Huateng Pharma proudly announces the launch of a groundbreaking suite of anti-diabetes intermediates, featuring key compounds such as Canagliflozin, [read full press release…]
Huateng Pharma Launches Exciting New Product Line – Fexuprazan and Vonoprazan Intermediates
Hunan, China, 2023-Oct-21 — /EPR Network/ — Huateng Pharma, a leading innovator in pharmaceutical intermediates, is proud to announce the introduction of its latest product [read full press release…]
Huateng Pharma Supplies Minoxidil Intermediate 2,4-Diamino-6-chloropyrimidine (CAS NO.156-83-2)
Hunan, China, 2023-Aug-21 — /EPR Network/ — Minoxidil was first introduced by Upjohn Company of the United States, and was first used as an oral [read full press release…]
Huateng Pharma Supplies Some Intermediates of CDK4/6 Inhibitors for Treatment of Advanced Breast Cancer
Hunan, China, 2023-Jul-15 — /EPR Network/ — Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes [read full press release…]
ADC Drugs For HER2 Positive Breast Cancer
Changsha City, China, 2023-Jul-03 — /EPR Network/ — According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer [read full press release…]
Development Trends And Potential Challenges of PROTACs
Watertown, MA, 2023-Apr-24 — /EPR Network/ — PROTAC technology has been in development for more than 20 years. PROTAC proof-of-concept studies date back to 2001, [read full press release…]
TPD Show Potential For The Treatment of Alzheimer’s Disease
Hunan, China, 2023-Mar-29 — /EPR Network/ — Targeted protein degradation (TPD) is a promising strategy in the field of drug discovery. In recent years, targeted [read full press release…]
Huateng Pharma Develops Systemic Antiparasitic Agent Fluralaner
Hunan, China, 2023-Jan-29 — /EPR Network/ — Fluralaner is a systemic insecticide and acaricide that can be administered orally or topically. Bravecto is the trade name. [read full press release…]
Ensitrelvir, An Oral Antiviral Drug For COVID-19 Treatment
Hunan, China, 2022-Apr-27 — /EPR Network/ — Ensitrelvir (code name S-217622, brand name Xocova), is a new inhibitor of the SARS-CoV-2 major protease (Mpro), also [read full press release…]
Huateng Pharma Develops Caronic Anhydride & Derivatives As Paxlovid Intermediates
Hunan Province, China, 2022-Mar-29 — /EPR Network/ — On February 16, 2022, the data on Paxlovid previously published by Pfizer and submitted to the FDA [read full press release…]
Is There A Link Between COVID-19 And Parkinson’s Disease
Hunan, China, 2021-Dec-23 — /EPR Network/ — Case reports of younger COVID-19 patients developing Parkinson’s disease within weeks of contracting the virus led researchers to [read full press release…]
Dolutegravir is a first-line treatment for newly diagnosed HIV patients
Hunan Province, China, 2021-Nov-24 — /EPR Network/ — A new study by UBC researchers is set to change international treatment recommendations for people who are [read full press release…]
The Relationship Between The Diagnosis of Diabetes And The Use of Antidepressants And Antipsychotics
Edinburgh, Scotland, 2021-Oct-19 — /EPR Network/ — Almost three in ten people with type 2 diabetes (T2D) in Scotland were prescribed antidepressants before they were [read full press release…]
